CY1120602T1 - [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων - Google Patents

[1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων

Info

Publication number
CY1120602T1
CY1120602T1 CY181100512T CY181100512T CY1120602T1 CY 1120602 T1 CY1120602 T1 CY 1120602T1 CY 181100512 T CY181100512 T CY 181100512T CY 181100512 T CY181100512 T CY 181100512T CY 1120602 T1 CY1120602 T1 CY 1120602T1
Authority
CY
Cyprus
Prior art keywords
multiplateric
pyridazines
triazolo
diseases
treatment
Prior art date
Application number
CY181100512T
Other languages
Greek (el)
English (en)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Michael James Waring
James Francis Mccabe
Steven Christopher Glossop
Arshed Mahmood
Zoe Ann Cotter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1120602T1 publication Critical patent/CY1120602T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Geology (AREA)
  • Mining & Mineral Resources (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Fluid Mechanics (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY181100512T 2014-07-28 2018-05-18 [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων CY1120602T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
CY1120602T1 true CY1120602T1 (el) 2019-12-11

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100512T CY1120602T1 (el) 2014-07-28 2018-05-18 [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων

Country Status (37)

Country Link
US (5) US9944650B2 (enExample)
EP (1) EP3174881B1 (enExample)
JP (1) JP6592503B2 (enExample)
KR (1) KR20170033427A (enExample)
CN (1) CN106536524B (enExample)
AP (1) AP2017009700A0 (enExample)
AU (1) AU2015295120B2 (enExample)
BR (1) BR112017001160A2 (enExample)
CA (2) CA2956421C (enExample)
CL (1) CL2017000223A1 (enExample)
CO (1) CO2017001918A2 (enExample)
CY (1) CY1120602T1 (enExample)
DK (1) DK3174881T3 (enExample)
DO (1) DOP2017000018A (enExample)
EA (1) EA032654B9 (enExample)
ES (1) ES2670444T3 (enExample)
GT (1) GT201700016A (enExample)
HR (1) HRP20180788T1 (enExample)
HU (1) HUE037571T2 (enExample)
IL (1) IL250104B (enExample)
LT (1) LT3174881T (enExample)
MX (1) MX374539B (enExample)
MY (1) MY187251A (enExample)
NI (1) NI201700006A (enExample)
NO (2) NO2719005T3 (enExample)
PE (1) PE20170527A1 (enExample)
PH (1) PH12017500159B1 (enExample)
PL (1) PL3174881T3 (enExample)
PT (1) PT3174881T (enExample)
RS (1) RS57242B1 (enExample)
SG (1) SG11201700419SA (enExample)
SI (1) SI3174881T1 (enExample)
SM (1) SMT201800260T1 (enExample)
SV (1) SV2017005368A (enExample)
TN (1) TN2017000018A1 (enExample)
WO (1) WO2016016618A1 (enExample)
ZA (1) ZA201701207B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (enExample) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
MX2022004555A (es) 2019-10-14 2022-07-21 Astrazeneca Ab Terapia de combinacion para tratar una neoplasia maligna hematologica.
JP2023509191A (ja) 2020-01-09 2023-03-07 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795273B2 (en) 2005-12-08 2010-09-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
EP2430024A1 (en) * 2009-05-11 2012-03-21 AstraZeneca AB [1,2,4]triazolo [4,3-b]pyridazines as ligands of the androgen receptor
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
WO2012174487A2 (en) * 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (enExample) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
MY187251A (en) 2021-09-15
KR20170033427A (ko) 2017-03-24
AU2015295120A8 (en) 2017-02-09
EA032654B1 (ru) 2019-06-28
SI3174881T1 (en) 2018-06-29
EP3174881B1 (en) 2018-03-28
AP2017009700A0 (en) 2017-01-31
PH12017500159A1 (en) 2017-07-10
IL250104A0 (en) 2017-03-30
PH12017500159B1 (en) 2020-12-09
US9944650B2 (en) 2018-04-17
NI201700006A (es) 2017-08-25
HUE037571T2 (hu) 2018-09-28
NO3174881T3 (enExample) 2018-08-25
PT3174881T (pt) 2018-05-25
ES2670444T3 (es) 2018-05-30
US11407755B2 (en) 2022-08-09
JP6592503B2 (ja) 2019-10-16
JP2017522338A (ja) 2017-08-10
SMT201800260T1 (it) 2018-07-17
US20200055861A1 (en) 2020-02-20
SG11201700419SA (en) 2017-02-27
US10407432B2 (en) 2019-09-10
EA201790179A1 (ru) 2017-07-31
AU2015295120A1 (en) 2017-02-02
SV2017005368A (es) 2017-05-12
CN106536524A (zh) 2017-03-22
DOP2017000018A (es) 2017-03-15
ZA201701207B (en) 2018-12-19
LT3174881T (lt) 2018-06-11
CO2017001918A2 (es) 2017-05-10
BR112017001160A2 (pt) 2017-11-14
MX374539B (es) 2025-03-06
DK3174881T3 (en) 2018-06-06
US20180230158A1 (en) 2018-08-16
WO2016016618A1 (en) 2016-02-04
GT201700016A (es) 2018-12-19
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
US20170210747A1 (en) 2017-07-27
EP3174881A1 (en) 2017-06-07
IL250104B (en) 2018-10-31
EA032654B9 (ru) 2019-07-31
CL2017000223A1 (es) 2017-08-25
CA2956421C (en) 2023-03-14
CA3185741A1 (en) 2016-02-04
TN2017000018A1 (en) 2018-07-04
US10766905B2 (en) 2020-09-08
AU2015295120B2 (en) 2018-02-01
PL3174881T3 (pl) 2018-08-31
US20210107905A1 (en) 2021-04-15
RS57242B1 (sr) 2018-07-31
US20230035133A1 (en) 2023-02-02
HRP20180788T1 (hr) 2018-06-29
NO2719005T3 (enExample) 2018-01-20
CA2956421A1 (en) 2016-02-04
CN106536524B (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CO2018011064A2 (es) Inhibidores de bromodominios
JOP20170135A1 (ar) مركبات ديازاسبيروألكيل مثيل-إندول
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
MX2015017964A (es) Inhibidores de bromodominio.
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
TW201613864A (en) Novel compounds
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MD20170011A2 (ro) Compuşi imidazopiridazinici
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний